vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Ribbon Communications Inc. (RBBN). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $162.6M, roughly 1.0× Ribbon Communications Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -10.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -8.1%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Ribbon Communications Inc. is a public company that makes software, IP and optical networking solutions for service providers, enterprises and critical infrastructure sectors. The company was formed in 2017, following the merger of Genband and Sonus Networks and is headquartered in Plano, Texas.

ESPR vs RBBN — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.0× larger
ESPR
$168.4M
$162.6M
RBBN
Growing faster (revenue YoY)
ESPR
ESPR
+154.0% gap
ESPR
143.7%
-10.3%
RBBN
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-8.1%
RBBN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
RBBN
RBBN
Revenue
$168.4M
$162.6M
Net Profit
$89.1M
Gross Margin
42.9%
Operating Margin
50.6%
37.6%
Net Margin
54.8%
Revenue YoY
143.7%
-10.3%
Net Profit YoY
EPS (diluted)
$0.32
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
RBBN
RBBN
Q1 26
$162.6M
Q4 25
$168.4M
$227.3M
Q3 25
$87.3M
$215.4M
Q2 25
$82.4M
$220.6M
Q1 25
$65.0M
$181.3M
Q4 24
$69.1M
$251.4M
Q3 24
$51.6M
$210.2M
Q2 24
$73.8M
$192.6M
Net Profit
ESPR
ESPR
RBBN
RBBN
Q1 26
$89.1M
Q4 25
Q3 25
$-31.3M
$-12.1M
Q2 25
$-12.7M
$-11.1M
Q1 25
$-40.5M
$-26.2M
Q4 24
Q3 24
$-29.5M
$-13.4M
Q2 24
$-61.9M
$-16.8M
Gross Margin
ESPR
ESPR
RBBN
RBBN
Q1 26
42.9%
Q4 25
53.3%
Q3 25
50.1%
Q2 25
49.6%
Q1 25
45.4%
Q4 24
55.7%
Q3 24
52.1%
Q2 24
50.8%
Operating Margin
ESPR
ESPR
RBBN
RBBN
Q1 26
37.6%
Q4 25
50.6%
4.1%
Q3 25
-11.4%
1.3%
Q2 25
8.6%
1.9%
Q1 25
-34.0%
-10.8%
Q4 24
-6.4%
13.2%
Q3 24
-31.0%
-0.4%
Q2 24
3.5%
-1.0%
Net Margin
ESPR
ESPR
RBBN
RBBN
Q1 26
54.8%
Q4 25
Q3 25
-35.9%
-5.6%
Q2 25
-15.4%
-5.0%
Q1 25
-62.2%
-14.5%
Q4 24
Q3 24
-57.2%
-6.4%
Q2 24
-83.9%
-8.7%
EPS (diluted)
ESPR
ESPR
RBBN
RBBN
Q1 26
$0.50
Q4 25
$0.32
$0.50
Q3 25
$-0.16
$-0.07
Q2 25
$-0.06
$-0.06
Q1 25
$-0.21
$-0.15
Q4 24
$-0.14
$0.05
Q3 24
$-0.15
$-0.08
Q2 24
$-0.33
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
RBBN
RBBN
Cash + ST InvestmentsLiquidity on hand
$167.9M
$67.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$419.1M
Total Assets
$465.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
RBBN
RBBN
Q1 26
$67.6M
Q4 25
$167.9M
$96.4M
Q3 25
$92.4M
$74.8M
Q2 25
$86.1M
$60.5M
Q1 25
$114.6M
$71.2M
Q4 24
$144.8M
$87.8M
Q3 24
$144.7M
$37.2M
Q2 24
$189.3M
$64.6M
Total Debt
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
$342.1M
Q3 25
$344.3M
Q2 25
$346.5M
Q1 25
$347.4M
Q4 24
$348.3M
Q3 24
$349.1M
Q2 24
$350.0M
Stockholders' Equity
ESPR
ESPR
RBBN
RBBN
Q1 26
$419.1M
Q4 25
$-302.0M
$449.0M
Q3 25
$-451.4M
$360.1M
Q2 25
$-433.5M
$370.4M
Q1 25
$-426.2M
$381.8M
Q4 24
$-388.7M
$404.6M
Q3 24
$-370.2M
$395.5M
Q2 24
$-344.2M
$405.0M
Total Assets
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
$465.9M
$1.2B
Q3 25
$364.0M
$1.1B
Q2 25
$347.1M
$1.1B
Q1 25
$324.0M
$1.1B
Q4 24
$343.8M
$1.2B
Q3 24
$314.1M
$1.1B
Q2 24
$352.3M
$1.1B
Debt / Equity
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
0.76×
Q3 25
0.96×
Q2 25
0.94×
Q1 25
0.91×
Q4 24
0.86×
Q3 24
0.88×
Q2 24
0.86×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
RBBN
RBBN
Operating Cash FlowLast quarter
$45.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
$45.2M
$29.2M
Q3 25
$-4.3M
$26.5M
Q2 25
$-31.4M
$-795.0K
Q1 25
$-22.6M
$-3.5M
Q4 24
$-35.0M
$61.8M
Q3 24
$-35.3M
$-14.8M
Q2 24
$-7.2M
$-9.8M
Free Cash Flow
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
$27.3M
Q3 25
$21.0M
Q2 25
$-6.5M
Q1 25
$-15.7M
Q4 24
$53.8M
Q3 24
$-35.5M
$-23.7M
Q2 24
$-7.3M
$-12.9M
FCF Margin
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
12.0%
Q3 25
9.7%
Q2 25
-2.9%
Q1 25
-8.7%
Q4 24
21.4%
Q3 24
-68.7%
-11.3%
Q2 24
-9.9%
-6.7%
Capex Intensity
ESPR
ESPR
RBBN
RBBN
Q1 26
Q4 25
0.0%
0.9%
Q3 25
0.0%
2.6%
Q2 25
0.0%
2.6%
Q1 25
0.0%
6.7%
Q4 24
0.0%
3.2%
Q3 24
0.3%
4.2%
Q2 24
0.1%
1.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

RBBN
RBBN

Service$94.5M58%
Product$68.1M42%

Related Comparisons